Cargando…
Disease progression and pseudoprogression following partial response with rare gingiva metastasis upon IBI308 (sintilimab) immunotherapy reflects the complexity of metastatic lung cancer: a case report
The differential diagnosis of progression and pseudoprogression is one difficulty in current immunotherapy. Since the time point and criteria for pseudoprogression diagnosis are not yet unified, current diagnosis and treatment rely on imaging and pathology. Here we report a 57-year-old Chinese male...
Autores principales: | Jiang, Haiping, Chen, Zhenguang, Gao, Yuan, Ding, Yongfeng, You, Qihan, Ye, Lei, Li, Lifeng, Liu, Guifeng, Song, Lele, Xu, Nong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798950/ https://www.ncbi.nlm.nih.gov/pubmed/35116284 http://dx.doi.org/10.21037/tcr-20-2736 |
Ejemplares similares
-
Cost‐effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China
por: Xu, Zhe, et al.
Publicado: (2023) -
Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events
por: Tu, Lingfang, et al.
Publicado: (2021) -
Ibis
por: Vargas Vila, José María, 1860-1933
Publicado: (1908) -
Pseudoprogression and Immunotherapy Phenomena
por: Waxman, Elizabeth S., et al.
Publicado: (2020) -
Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma
por: Garcia, Diogo, et al.
Publicado: (2021)